期刊文献+

中西医结合治疗晚期胃癌生存期分析 被引量:38

Survival time of advanced gastric cancer patients treated with integrated traditional Chinese and Western medicine therapy
下载PDF
导出
摘要 背景:晚期胃癌生存率低,中医药治疗胃癌有抑瘤、延长带瘤生存期和提高生活质量等作用。目的:观察中西医结合治疗对晚期胃癌患者生存期和生活质量的影响。设计、场所、受试者和干预措施:共95例患者入组,分为综合组48例和对照组47例。综合组为上海龙华医院肿瘤一科住院晚期胃癌患者,按上海龙华医院肿瘤一科胃癌中西医结合诊疗常规进行中药结合化疗的治疗,同期收集的上海仁济医院和瑞金医院单纯化疗患者为对照组,对照组患者不服用中药。主要结局指标:随访和比较两组患者的生存时间。观察综合组生活质量,包括Karnofsky评分、体质量和欧洲癌症研究与治疗组织生活质量问卷(The European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire,EORTC QLQ-C30)评分,并计算有效率,观察化疗毒副反应。结果:综合组预计中位生存时间为16.12个月,长于对照组的9.64个月(P<0.05)。综合组QLQ-C30生活质量核心量表中功能子量表和症状子量表评分均下降,总健康状况子量表分数上升,表明生活质量有改善。治疗后体质量较治疗前有所增长(P=0.037),而Karnofsky评分治疗前后比较,差异无统计学意义(P=0.061)。综合组所有患者均为可评价病例,完全缓解0例,部分缓解3例,疾病稳定34例,疾病进展11例,部分缓解率为6.25%(3/48),疾病控制率为77.08%(37/48)。未见因严重化疗不良反应而终止治疗者,也无化疗相关死亡病例。结论:中西医结合治疗晚期胃癌能延长生存期,改善患者生活质量,提高综合疗效。 Background: Advanced gastric cancer has a low survival rate while traditional Chinese medicine (TCM) therapy has effects in inhibiting tumor growth, lengthening survival time and improving the quality of life. Objective: To analyze the effects of integrated traditional Chinese and Western medicine therapy on the survival time and quality of life of advanced gastric cancer patients. Design, setting, participants and interventions: A total of 95 advanced gastric cancer patients were enrolled and divided into comprehensive group (48 cases) and control group (47 cases). The patients in the comprehensive group from the First Department of Oncology, Longhua Hospital, were treated with TCM therapy and chemotherapy based on the gastric cancer treatment guidelines made by the First Department of Oncology of Longhua Hospital, and the patients in the control group from Renji Hospital and Ruijin Hospital in Shanghai were treated with chemotherapy only. Main outcome measures: The survival time in the two groups were observed and compared. The Karnofsky score, body weight, the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) score, response rate and chemotherapy-related adverse events in the comprehensive group were observed. Results: The estimated median survival time in the comprehensive group was 16.12 months, longer than 9.64 months in the control group (P〈0.05). The scores of function and symptom of EORTC QLQ-C30 in the comprehensive group decreased, while the overall health status increased, and the results indicated that the quality of life of the patients in the comprehensive group was improved. In the comprehensive group, the body weight after treatment was higher than that before treatment (P=0.037), while there was no difference in Karnofsky scores between that before and after treatment (P=0.061). All the patients in the comprehensive group were assessable. The complete response rate was 0, 3 cases had a partial response, 34 cases had stable disease, and 11 cases had disease progression. The overall response rate was 6.25% (3/48), and the disease control rate was 77.08% (37/48). No patient withdrew because of severe adverse events and there was no chemotherapy-related death. Conclusion: Integrated traditional Chinese and Western medicine can prolong the survival time and improve the quality of life of advanced gastric cancer patients, and enhance the comprehensive effects.
出处 《中西医结合学报》 CAS 2010年第2期116-120,共5页 Journal of Chinese Integrative Medicine
关键词 胃癌 中西医结合疗法 生存期 生活质量 临床对照试验 gastric cancer integrated traditional Chinese and Western medicine therapy survival time quality of life controlled clinical trial
  • 引文网络
  • 相关文献

参考文献17

  • 1Van Cutsem E. The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist. 2004; 9(Suppl 2): 9-15.
  • 2秦叔逵,龚新雷.晚期胃癌化疗的现状和新进展[J].临床肿瘤学杂志,2006,11(9):641-652. 被引量:269
  • 3孙大志,许玲,姜林娣,魏品康.中医药治疗胃癌临床研究文献质量的调查评价[J].中国临床医学,2003,10(6):833-835. 被引量:26
  • 4中国抗癌协会.新编常见恶性肿瘤诊治规范.第2版.北京:中国协和医科大学出版社.1999.
  • 5Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of West ern and oriental trials. Cancer. 1999, 86 (9): 1657 -1668.
  • 6沈自尹 王文健.中医虚证辨证参考标准[J].中西医结合杂志,1986,6(10):598-598.
  • 7中华人民共和国卫生部.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002.362,371.
  • 8金懋林.晚期胃癌的化学治疗[J].中国实用外科杂志,2000,20(10):628-630. 被引量:13
  • 9Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kohayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trials): a phase III trial. Lancet Oncol. 2008; 9(3): 215-221.
  • 10Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR; Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitahine and oxaliplatin for advanced esophagogastric cancer. N EnglJ Med. 2008; 358(1): 36-46.

二级参考文献44

共引文献1000

同被引文献501

引证文献38

二级引证文献226

;
使用帮助 返回顶部